MRD_Screening_Of_Human_B_ALL. MRD_Screening_Of_Human_B_ALL
收藏NIAID Data Ecosystem2026-03-08 收录
官方服务：
资源简介：
MRD screening in Human B-ALL: monitoring B-cell repertoires in longitudinal samples of patients.
应用场景：
创建时间：
2015-09-04
相关数据集
Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements
IGH gene rearrangement and IGK-Kde gene deletion can be used as molecular markers for the assessment of B lineage acute lymphoblastic leukemia (B-ALL). Minimal residual disease detected based on those
Figshare2017-01-01 更新130
Antibody repertoire sequencing of human tonsillar B cell subsets. Antibody repertoire sequencing of human tonsillar B cell subsets
In response to antigen challenge, human B cells clonally expand, undergo selection and differentiate within secondary lymphoid tissues to produce mature B cell subsets and high affinity antibodies nec
NIAID Data Ecosystem100
Dataset from U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire- Year 1, 2009
This is an exploratory study using a strategy that has not been previously employed to investigate the effects of age and vaccine type on specific kinds of immune responses to licensed, seasonal 200
NIAID Data Ecosystem60
Supplementary Material for: Monitoring minimal residual disease in RUNX1-mutated acute myeloid leukemia
Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerf
Figshare2022-08-05 更新120
Measuring Minimal Residual Disease beyond 10-5 through IGHV leader-based NGS increases Prognostic Discrimination in Chronic Lymphocytic Leukemia. Measuring Minimal Residual Disease beyond 10-5 through IGHV leader-based NGS increases Prognostic Discrimination in Chronic Lymphocytic Leukemia
The sensitivity of conventional techniques for the quantification of minimal/measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) is limited to MRD 10-4. Measuring MRD <10-4 could h
NIAID Data Ecosystem80
